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Introduction
The accelerating production and use of engineered nanomaterials (NMs) raises questions about the
safety of this new technology. To avoid the possible hazards associated with NMs requires proper
regulation. How should toxicity testing be addressed and can standard tests for assessment of safety
of chemicals be applied to NMs? What are the major limitations of NM safety testing and is the
current regulatory testing strategy suitable also for NMs? Can existing tests be fully adapted or
should new methods be developed to suit the unique properties of NMs?
Nanomaterials and Nanoparticles
NMs are nanometer-scale materials that present at least one of their dimensions 100 nm or less.
Nanoparticles are NMswith all three dimensions within 100 nm (http://ec.europa.eu/environment/
chemicals/nanotech/index.htm#definition; Magdolenova et al., 2014). (In nanomedicine nanoscale
particles larger than 100 nm are still considered as NMs.) The small size makes NMs very
reactive, as the relative increase in surface area leaves a higher number of molecules to react
with the environment. Thus, in their physical, chemical and biological properties, NMs are very
different from the bulk material with the same chemical composition. On account of these
unique characteristics they have found applications in a wide range of areas: technology, energy,
construction, electronics, agriculture, optics, paint, textiles, food, cosmetics, medicine. . . The
production of NMs has impressively increased in the last two decades and nowadays humans are
exposed to an unknown amount of a great variety of NMs used in the production of daily life
products.
Genotoxicity Assessment of Nanonanomaterials
The same characteristics that make NMs interesting for many applications can also lead to toxicity.
Thus concern about the potential harmful effect of NMs on human health has increased. NMs can
enter the cell, interact with cell components and persist in cells with consequent chronic toxicity.
A new research area that explores the potential toxicity of NMs in human and the environment
is nanotoxicology. Within the nanotoxicology field, nanogenotoxicology studies the effect of NMs
on DNA.
NMs can also enter into the nucleus, intentionally (i.e., in nanomedicine) or unintentionally,
and there might interact with DNA, causing genetic damage (DNA breaks, altered bases or
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chromosomal damage). They can also reach the nucleus during
mitosis and interfere with the microtubules, causing clastogenic
effects. NMs can interact with cellular and mitochondrial
membranes or alter mitochondrial function, provoking the
production of reactive oxygen and nitrogen species and inducing
DNA oxidation. Inflammation produced by NMs in tissues can
also affect DNA. NMs can even induce genotoxic effects by
depleting the antioxidant defenses or altering the DNA repair
systems. All these events may result in pre-mutagenic lesions that
can lead to mutations and possibly to cancer and other diseases.
Genotoxicity endpoints are crucial in assessing the safety
of chemicals. The Organisation for Economic Co-operation
and Development (OECD1 ) has published guidelines for
several validated and standardized in vitro and in vivo
methods including genotoxicity assays covering different
endpoints (http://www.oecd.org/chemicalsafety/testing/
oecdguidelinesforthetestingofchemicals.htm). It is clear that the
strategies and the standardized protocols used for characterizing
the potential toxicity of chemicals might not be fully suitable
for assessing the safety of NMs. NMs can interfere with assay
components or detection systems of standard toxicity tests
(Guadagnini et al., 2015). In 2006, the OECD created a Working
Party on Manufactured Nanomaterials (WPMN) with the aim
to review the OECD guidelines for genotoxicity and assess their
suitability for NMs.
In 2009 the OECDWPMN published a report recommending
the bacterial reverse mutation (Ames test) (OECD TG 4712
), mammalian chromosome aberration (OECD TG 4733 ) and
mammalian cell genemutation (OECDTG4764 ) tests for in vitro
testing; and the mammalian erythrocyte micronucleus (OECD
TG 4745 ), mammalian bone marrow chromosome aberration
(OECD TG 4756 ) and mammalian liver unscheduled DNA
synthesis (UDS) (OECD TG 4867 ) tests for in vivo testing
(OECD, 20098). However, the Ames test is not suitable for NMs
because there is limited or no penetration through the bacterial
wall. Thus it is not surprising that NMs exhibiting a positive
response in in vitro mammalian cell tests have shown negative
results in the Ames test (Landsiedel et al., 2009; Doak et al., 2012;
Jomini et al., 2012; Woodruff et al., 2012). In the case of the in
vitro micronucleus test, the interaction between cytochalasin B
and NMs is a limiting factor. Cytochalasin B inhibits cytokinesis
1OECD guidelines for the testing of chemicals; http://www.oecd-ilibrary.org/
environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-
effects_20745788
2 OECD. Test Guideline 471. Bacterial reverse mutation test, 1997. In OECD
Guidelines for Testing of Chemicals.
3OECD. Test Guideline 473. In vitro mammalian chromosome aberration test,
2014. In: OECD Guidelines for testing of chemicals.
4OECD. Test Guideline 476. In vitromammalian cell gene mutation test, 1997. In:
OECD Guidelines for testing of chemicals.
5OECD. Test Guideline 474. Mammalian erythrocyte micronucleus, 2014. In:
OECD Guidelines for testing of chemicals.
6OECD. Test Guideline 475. Mammalian bone marrow chromosome aberration
test, 2014. In: OECD Guidelines for testing of chemicals.
7OECD. Test Guideline 486. Unschedule DNA synthesis (USD) test with
mammalian liver cells in vivo, 1997. In: OECD Guidelines for testing of chemicals.
8OECD. 2009. Preliminary Review of OECDTest Guidelines for their Applicability
to Manufactured Nanomaterials. Series of Safety of Manufactured Nanomaterials
No. 15.
and is used to generate the binucleated cells but it also inhibits
endocytosis, an important mechanism of uptake of NMs into
the cell (Doak et al., 2009; Gonzalez et al., 2011). NMs were
also seen in the slides when high concentrations of NMs were
tested (Pfaller et al., 2010) though this does not seem to be a
problem.
Last year, the OECD WPMN published a new report
about the genotoxicity evaluation of NMs (OECD, 20149 ).
The Ames test was not recommended for the investigations
of the genotoxicity of NMs for the reason explained above.
Modification of the in vitro micronucleus assay was discussed
to ensure the exposure of the cells to the NMs in the absence of
cytochalasin B.
Although a lot of effort is being made to develop a testing
strategy to assess the genotoxicity of NMs in a reliable way, a
consensus on regulatory requirements is still needed. According
to the last OECD WPMN report there is a need for an assay
that identifies and characterizes the DNA damage induced
by secondary mechanisms (e.g., oxidative stress induced by
inflammation) (OECD, 2014). Moreover, a complete strategy
to assess the genotoxicity of NMs should cover different
mechanisms and endpoints including assays to detect strand
breaks and altered DNA bases.
The Comet Assay in Genotoxicity Testing
The comet assay is widely used in in vitro and in vivo genotoxicity
testing. It measures DNA strand breaks and alkali-labile sites
in virtually any eukaryotic cell including cells isolated from
tissues. Its modificationwithDNA repair enzymes, which convert
the specific lesions to breaks, makes the assay more versatile
(e.g., formamidopyrimidine DNA glycosylase, FPG, detects 8-
oxoguanine and other purine oxidation products). The in vivo
comet assay, in its standard version, has been validated and
the OECD guideline was published last September (OECD TG
48910 ); this assay can be applied in many animal tissues,
a great advantage when organ-specific toxicity is expected or
investigated. The role of the in vitro comet assay in regulatory
toxicity is currently not defined but efforts are being made to
validate it. Nevertheless, it is recommended as an appropriate
test under the Registration, Evaluation, Authorisation and
Restriction of Chemicals Substances programme of the European
Commission (REACH), is accepted by the European Food
Safety Authority (EFSA) and is widely used for screening novel
cosmetics and pharmaceuticals. It is also the most used assay
in assessing the genotoxic potential of NMs. Magdolenova et al.
(2014) reviewed genotoxicity techniques used in 112 papers,
published from 2000 to 2012, where the potential genotoxicity
of NMs was studied. Similarly, Azqueta et al. (2014) reviewed
102 papers where the genotoxicity of NMs with a potential
application in medicine was assessed. According to the results
of both reviews (Table 1), where the authors of this paper were
directly involved, the comet assay and the micronucleus test are
9OECD. 2014. Genotoxicity of manufactured nanomaterials: report of the OECD
expert meeting. Series of Safety of Manufactured Nanomaterials No. 43.
10OECD. Test Guideline 489. In vivo mammalian alkaline comet assay, 2014. In:
OECD Guidelines for testing of chemicals.
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different assays.
the most used techniques in vitro and in vivo, the comet assay
being the most used in in vitro and the micronucleus test in
in vivo studies.
Some interactions of NMs with the comet assay have been
described though most of them are hypothetical. Some authors
have described the presence of NMs in the comets, which implies
that they were also present during the performance of the assay
and could have interacted with the naked DNA inducing artificial
additional damage (Stone et al., 2009; Karlsson, 2010). However,
Magdolenova et al. (2012) found with 5 NMs that their presence
in the gel does not affect the comet tail. Karlsson et al. (2015)
discussed different possibilities of interference of NMs with the
assay and concluded that under normal experimental conditions
the additional damage is unlikely to be significant. NMs present
in the comets could also interfere with the staining of the comets.
Karlsson et al. (2015) suggest that, though there is no indication
of this phenomenon, the visual scoring of the comets (rather than
computerized image analysis) can be useful.
Interference of FPG with the comet assay (Kain et al., 2012)
is also unlikely when applied correctly in the test (Magdolenova
et al., 2012). On the other hand, caution is needed with
photocatalytic NMs as they can induce additional breaks when
the slides are exposed to normal light during their processing
(Karlsson et al., 2015).
The comet assay has not been mentioned by the OECD
WPMN as a potential appropriate test for testing NMs. The
in vitro version of the assay does not have an OECD guideline
yet though an in vivo versions was accepted in September
2014 (OECD TG 489), about 2 months before the publication
of the OECD WPMN report on genotoxicity evaluation of
MNs (OECD, 2014). The comet assay is considered as an
indicator test detecting intermediate DNA lesions that can be
repaired or fixed into mutations. Nevertheless, both in vitro
and in vivo comet assays can complete the strategy to assess
the genotoxicity of NMs since with the lesion-specific enzymes
DNA lesions such as oxidized bases can be detected, additionally
to DNA breaks. Moreover, the in vivo version is also suitable
to detect DNA damage induced by secondary mechanisms
such as oxidative stress induced via inflammation in several
organs.
Conclusion
Nanotechnology promises enormous benefits to society but
also brings new challenges. One of them is the safety of new
materials, and consequently there is a growing need for NM
toxicity testing, Recent regulations based on hazard assessment
of chemicals are not fully fit for purpose for testing NMs as
current methods to assess NM toxicity do not always take
into account the specific features of NMs. For example, some
OECD-recommended tests for genotoxicity (Ames test), are not
applicable, or need modification to avoid interference of tested
NMs with the test system (micronucleus test). The comet assay
has proved to be a sensitive and relatively simple method to study
specific DNA lesions such as single and double strand breaks,
oxidation and alkylation lesions or cross links. It is so far themost
used method in nanogenotoxicology and has great potential to
be included in a test battery due to its robustness, versatility and
reliability.
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